In this article, the "Dissolution" test, which is one of the most important indicators in the production process of "STIGMACOLE" capsules, was developed. To do this, the "in vitro" method was used in laboratory conditions. In the development of the solubility test of "STIGMACHOLE" capsules based on scientific results, using the method presented in the first edition of the State Pharmacopoeia of the Republic of Uzbekistan, the "Rotating " device was used. The rate of release of active biologically active substances (BFM) contained in the capsule and the pH index of the environment were analyzed using the " rotating equipment " device. During the study, purified water (pH=5.8), 0.1 molar hydrochloric acid (pH=1.3), 0.1 molar solution of sodium bicarbonate (pH=8), 0.01 molar sodium tetraborate (pH=9, 2) was performed using such solutions. As a result of the research, the "in vitro" method developed a suitable "Dissolution" test for "STIGMACHOLE" capsules.

State Pharmacopoeia of the Republic of Uzbekistan. Tashkent. -2021. Volume 1, Part 1-2.

Gosudarstvennaya pharmacopoeia Rossiyskoy Federasii, X I izd., Moscow (2018); [Electronic resource], URL : https :// femb . ru / re c ord / pharma c opea 14 .

Shodieva N.B., Yunusova H.M. Studies on studying the biopharmaceutical properties and stability of "STIGER-S" tablet// Pharmaceutical Bulletin of Uzbekistan. – 2017. No. 2. B. 10-15.

Maksudova FX, Mamatkulov ZU, Baratova MB, Mirzakamalova DS Biopharmaceutical study of general tonic capsules by in vitro method// European journal of life safety and stability-. 2021.-Volume 12. (ejlss) issn 2660-9630.-r.338-3342.

Ilhamova N.B., Djalilova H.K. Biofarmatsevticheskie issledovaniya tabletok "Nime-S" method in vitro // Pharmaceutical notice of Uzbekistan.-2016. #2.-S.26-28.

Maksudova F.Kh. Biofarmatsevticheskie issledovaniya kombinirovannyx kapsul nesteroidnogo protivovospalitelnogo deystviya // Farmatsevticheskiy zurnal. - Tashkent . - 2016.-No. 1. -S.88-91.

Komilova M.M., Karieva Yo.S., Mirzakamolova D.S. Determining the conditions for conducting the "Solubility" test for Efavirenz capsules // Pharmacy. – 2024. #4. B.37-41